不同的表观遗传机制区分 TMPRSS2-ERG 融合阳性和阴性前列腺癌。
Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers.
机构信息
Oregon Health & Science University, Knight Cancer Institute, Portland, OR 97239, USA.
出版信息
Cancer Discov. 2012 Nov;2(11):979-81. doi: 10.1158/2159-8290.CD-12-0392.
Abstract
This issue of Cancer Discovery features an article that describes distinct epigenetic mechanisms that operate in TMPRSS2-ERG fusion-negative prostate cancers. This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype.
摘要
本期《癌症发现》杂志有一篇文章描述了 TMPRSS2-ERG 融合阴性前列腺癌中存在的独特表观遗传机制。这一发现阐明了这些 TMPRSS2-ERG 融合阴性肿瘤的分子特征，并可能对如何治疗这种前列腺癌亚型产生影响。
相似文献
1
Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers.不同的表观遗传机制区分 TMPRSS2-ERG 融合阳性和阴性前列腺癌。
Cancer Discov. 2012 Nov;2(11):979-81. doi: 10.1158/2159-8290.CD-12-0392.
2
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.TMPRSS2-ERG 融合阴性前列腺癌中的全基因组 DNA 甲基化事件提示存在 EZH2 依赖性机制，伴有 miR-26a 的高甲基化。
Cancer Discov. 2012 Nov;2(11):1024-35. doi: 10.1158/2159-8290.CD-12-0041. Epub 2012 Aug 28.
3
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.雄激素受体、多梳、TMPRSS2-ERG 基因融合在前列腺癌进展中的整合网络。
Cancer Cell. 2010 May 18;17(5):443-54. doi: 10.1016/j.ccr.2010.03.018.
4
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.zeste同源物2增强子（EZH2）的过表达是侵袭性前列腺癌亚群的特征，并且独立于术前和术后评估的临床病理参数预测患者预后。
Carcinogenesis. 2015 Nov;36(11):1333-40. doi: 10.1093/carcin/bgv137. Epub 2015 Sep 21.
5
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.TMPRSS2-ERG融合性高级别前列腺上皮内瘤变的特征及潜在临床意义
Clin Cancer Res. 2008 Jun 1;14(11):3380-5. doi: 10.1158/1078-0432.CCR-07-5194.
6
EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.EZH2 诱导的赖氨酸 K362 甲基化增强前列腺癌中的 TMPRSS2-ERG 致癌活性。
Nat Commun. 2021 Jul 6;12(1):4147. doi: 10.1038/s41467-021-24380-6.
7
[TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].[转移性前列腺癌中的TMPRSS2-ERG基因融合：细针穿刺标本研究]
Zhonghua Bing Li Xue Za Zhi. 2011 Jun;40(6):392-6.
8
miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer.miR-221 在 TMPRSS2:ERG 融合阳性前列腺癌中下调。
Anticancer Res. 2011 Feb;31(2):403-10.
9
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.通过易位或间质性缺失形成的TMPRSS2:ERG融合在雄激素依赖性前列腺癌中高度相关，但在晚期雄激素受体阴性前列腺癌中则不存在。
Cancer Res. 2006 Nov 15;66(22):10658-63. doi: 10.1158/0008-5472.CAN-06-1871.
10
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.在前列腺癌中，N-myc下游调控基因1（NDRG1）与ERG融合。
Neoplasia. 2009 Aug;11(8):804-11. doi: 10.1593/neo.09572.
引用本文的文献
1
Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.系统分析揭示了 ERG 阴性前列腺癌的分子特征。
Sci Rep. 2018 Aug 27;8(1):12868. doi: 10.1038/s41598-018-30325-9.
2
KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.KDM8/JMJD5 作为 AR 和 PKM2 的双重共激活因子，整合了 CRPC 中的 AR/EZH2 网络和肿瘤代谢。
Oncogene. 2019 Jan;38(1):17-32. doi: 10.1038/s41388-018-0414-x. Epub 2018 Aug 2.
3
Kaiso, a transcriptional repressor, promotes cell migration and invasion of prostate cancer cells through regulation of miR-31 expression.Kaiso是一种转录抑制因子，它通过调控miR-31的表达来促进前列腺癌细胞的迁移和侵袭。
Oncotarget. 2016 Feb 2;7(5):5677-89. doi: 10.18632/oncotarget.6801.
本文引用的文献
1
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.TMPRSS2-ERG 融合阴性前列腺癌中的全基因组 DNA 甲基化事件提示存在 EZH2 依赖性机制，伴有 miR-26a 的高甲基化。
Cancer Discov. 2012 Nov;2(11):1024-35. doi: 10.1158/2159-8290.CD-12-0041. Epub 2012 Aug 28.
2
Cancer statistics, 2012.癌症统计数据，2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
3
A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer.基于 DNA 甲基化微阵列的研究发现 ERG 是前列腺癌中常见的甲基化基因。
Epigenetics. 2011 Oct 1;6(10):1248-56. doi: 10.4161/epi.6.10.17727.
4
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
5
Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98.EZH2 基因在复发性鼻咽癌中过表达，并受 miR-26a、miR-101 和 miR-98 的调控。
Cell Death Dis. 2010 Oct 21;1(10):e85. doi: 10.1038/cddis.2010.64.
6
The genomic complexity of primary human prostate cancer.原发性人类前列腺癌的基因组复杂性。
Nature. 2011 Feb 10;470(7333):214-20. doi: 10.1038/nature09744.
7
Diverse somatic mutation patterns and pathway alterations in human cancers.人类癌症中的多种体细胞突变模式和通路改变。
Nature. 2010 Aug 12;466(7308):869-73. doi: 10.1038/nature09208. Epub 2010 Jul 28.
8
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.雄激素受体、多梳、TMPRSS2-ERG 基因融合在前列腺癌进展中的整合网络。
Cancer Cell. 2010 May 18;17(5):443-54. doi: 10.1016/j.ccr.2010.03.018.
9
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.微小RNA - 101的基因组缺失导致癌症中组蛋白甲基转移酶EZH2的过表达。
Science. 2008 Dec 12;322(5908):1695-9. doi: 10.1126/science.1165395. Epub 2008 Nov 13.
10
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.转移性前列腺癌中瘤内雄激素的维持：去势抵抗性肿瘤生长的一种机制。
Cancer Res. 2008 Jun 1;68(11):4447-54. doi: 10.1158/0008-5472.CAN-08-0249.
Zotero 插件